Список литературы

1. Wilkinson E.J., Teixeira M.R. Tumors of the vulva. In: Pathology and genetics of tumors of the breast and female genital organs. Ed. by F.A. Tavassoli, P. Devilee. Lyon: IARC Press, 2003. Pp. 314 - 334.

2. Oonk M.H.M., Planchamp F., Baldwin P. et al. European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer. 2017; 27(4): 832-7.

3. Hacker N.F. Vulvar cancer. In: Berek and Hacker's gynecologic oncology. Ed. by J.S. Berek, N.F. Hacker. 5^th ed. Philadelphia: Lippincott Williams & Wilkins, 2009. Pp. 536 - 575.

4. Ашрафян Л.А., Харченко Н.В., Киселев В.И. и др. Рак вульвы: этиопатогенетическая концепция. М.: Молодая гвардия, 2006. С. 7 - 38.

5. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7 - 30.

6. WHO classification of tumours of female reproductive organs. Ed. by R.J. Kurman, M.L. Carcangiu, C.S. Herrington, R.H. Young. IARC: Lyon 2014.

7. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.

8. Коржевская Е.В., Кузнецов В.В. Рак вульвы. Клиническая онкогинекология. Руководство для врачей. Под ред. В.П. Козаченко. 2-е изд., перераб. и доп. М.: Бином, 2016. С. 72 - 96.

9. Кузнецов В.В., Коржевская Е.В. Плоскоклеточный рак вульвы. Рациональная фармакотерапия в онкологии. Руководство для практикующих врачей. Под общ. ред. М.И. Давыдова, В.А. Горбуновой. М.: Литтерра, 2015. С. 441 - 444.

10. Slomovitz B.M., Coleman R.L., Oonk M.H. et al. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol 2015; 138: 472-7.

11. Kamran M.W., O'Toole F., Meghen K. et al. Whole-body [18F]fluoro-2deoxyglucose positron emission tomography scan as combined PETCT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis. Eur J Gynaecol Oncol 2014; 35: 230-5.

12. Koh WJ et al. Vulvar Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology./https://www.nccn.org/professionals/physician_gls/pdf/vulvar_blocks.pdf.

13. Moore D.H., Ali S., Koh W.J. et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012; 124(3): 529-33.

14. Petereit D.G., Mehta M.P., Buchler D.A., Kinsella T.J. Inguinofemoral radiation of N0, N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 1993; 27: 963-7.

15. Hallak S., Ladi L., Sorbe B. Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma. Int J Oncol 2007; 31: 1077-85.

16. Mahner S., Jueckstock J., Hilpert F.J. et. al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. Natl Cancer Inst 2015; 107(3).

17. Byfield J.E., Calabro-Jones P., Klisak I., Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X-rays. Int J Radiat Oncol Biol Phys 1982; 8(11): 1923-33.

18. Moore D.H., Thomas G.M., Montana G.S. et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42: 79 - 85.

19. Thomas G., Dembo A., DePetrillo A. et al. Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol Oncol 1989; 34(3): 263-7.

20. Wahlen S.A., Slater J.D., Wagner R.J. et al. Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. Cancer 1995; 75: 2289-94.

21. Sebag-Montefiore D.J., McLean C., Arnott S.J. et al. Treatment of advanced carcinoma of the vulvawith chemoradiotherapy - can exenterative surgery be avoided? Int J Gynecol Cancer 1994; 4: 150-5.

22. Mell L.K., Mundt A.J., Survey of IMRT use in the United States, 2004. Cancer 2005; 104: 1296-303.

23. Lim K., Small W., Pertelance L. et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2011; 79: 348-55.

24. Raspagliesi F et al. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva./ J Gynecol Oncol. 2014 Jan; 25(1): 22-9. doi: 10.3802/jgo.2014.25.1.22. Epub 2014 Jan 8.

25. Raitanen M., Rantanen V., Kulmala J. et al. Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines Int J Cancer 2002; 97: 853-7.

26. Raitanen M., Rantanen V., Kulmala J. et al. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. Int J Cancer 2002; 100: 238-43.

27. Gill B.S., Bernard M.E., Lin J.F. et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis. Gynecol Oncol 2015; 137(3): 365-72.

28. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015; 22(13): 4117-23.

29. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013; 92: 715-27.

30. Nilsson H., , Bock D. et al. Is preoperative physical activity related to post-surgery recovery? BMJ Open 2016; 6(1): e007997.

31. Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017; 39: 156-62.

32. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015; 22(13): 4117-23.

33. Carter J. Fast-track surgery in gynaecology and gynaecologic oncology: a review of a rolling clinical audit. ISRN Surgery 2012; 2012: 368014.

34. Nelson G., Bakkum-Gamez J., Kalogera E. et al Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations - 2019 update. Int J Gynecol Cancer 2019 Mar 15.

35. De Almeida E.P.M., De Almeida J.P., Landoni G. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Br J Anaesth 2017; 119(5): 900-7.

36. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010; 210(4): 491-5.

37. Peedicayil A., Weaver A., Li X. et al. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 2011; 121(1): 64-9.

38. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2010; 8: 1046-86.

39. Ben-Arye E., Samuels N., Lavie O. Integrative medicine for female patients with gynecologic cancer. J Altern Complement Med 2018; 24(9-10): 881-9.

40. Goerling U., Jaeger C., Walz A. et al. The efficacy of psycho-oncological interventions for women with gynaecological cancer: a randomized study. Oncology 2014; 87: 114-24.

41. Smits A., Lopes A., Bekkers R. et al. Body mass index and the quality of life of endometrial cancer survivors - a systematic review and meta-analysis. Gynecol Oncol 2015; 137: 180-7.

42. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42: 1409-26.

43. Zhou Y., Chlebowski R., LaMonte M.J. et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women"s Health Initiative. Gynecol Oncol 2014; 133(1): 4-10.

44. Biglia N., Zanfagnin V., Daniele A. et al. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 2017; 37(8): 4005-15.

45. Oonk. M. H.M. et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer/Int J Gynecol Cancer 2017; 27: 832Y837.

46. Amant, F., Nooij, L., Annibali, D., van Rompuy, A.-S., Han, S., van den Bulck, H., & Goffin, F. (2018). Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer. Gynecologic and Obstetric Investigation, 1-7. doi: 10.1159/000487435.

47. Witteveen P.O.et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group)./Ann Oncol. 2009 Sep; 20(9): 1511-6. doi: 10.1093/annonc/mdp043. Epub 2009.

48. Shields LBE, Gordinier ME Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature./Gynecol Obstet Invest. 2019; 84(1): 94-98. doi: 10.1159/000491090. Epub 2018.

49. Santeufemia D. A. Et al. Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases./Eur J Gynaecol Oncol. 2012; 33(4): 421-422

50. Peri M. A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression/Case Reports in Oncological Medicine Volume 2019, Article ID 1018492, 4 pages https://doi.org/10.1155/2019/1018492.

51. Rose PG et al Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer./N Engl J Med. 1999 Apr 15; 340(15): 1144-53.

52. Minig L. Clinical outcomes after fast-track care in women undergoing laparoscopic hysterectomy/ Int J Gynaecol Obstet. 2015 Dec; 131(3): 301-4. doi: 10.1016/j.ijgo.2015.06.034. Epub 2015 Sep 8.

53. Borman Р. Lymphedema diagnosis, treatment, and follow-up from the view point of physical medicine and rehabilitation specialists. Turk J Phys Med Rehab 2018; 64(3): 179-97.

54. Shimizu A et al. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers./ Int J Gynaecol Obstet. 2019 Nov; 147(2): 252-257. doi: 10.1002/ijgo.12944. Epub 2019 Aug 29.

55. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6): 649-655.

56. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191-205.

57. Raspagliesi F. et al. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. J Gynecol Oncol. 2014 Jan; 25(1): 22 - 29. https://doi.org/10.3802/jgo.2014.25.1.22.

58. Bellati F., et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases (2005) Gynecologic Oncology, 96 (1), pp. 227 - 231.

59. Long HJ., et al. "Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study". Journal of Clinical Oncology 23.21 (2005): 4626-4633.

60.Rose PG., et al. "Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study". Journal of Clinical Oncology 17.9 (1999): 2676-2680.

61. Lepori S, Fontanella C, Maltese G et al. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma. Annals of Oncology, 2017, 28: mdx372.053.